Severe Heart Failure Clinical Trial
— EFFICARDOfficial title:
Comparison of Patient Care Management Strategies of Heart Failure in the Rhône-Alpes Region. A Clinical and Economic Study.
| Verified date | February 2018 |
| Source | Hospices Civils de Lyon |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The heart failure is a chronic pathology with prevalence from 2 to 3% of general population,
a death rate of 50% at 6 months for patients with stage IV, and a probability of death or
hospitalization or emergency consultation of 40% at 3 years. The care of patients is
heterogeneous, especially in light of the organization of therapeutic education offered to
patients and patient monitoring modalities.
The aim of this study is to investigate the management strategies for patients with chronic
heart failure stage III or IV NYHA, and heart failure patients with stage II NYHA with
previous hospitalization for heart failure.
This is a longitudinal observational multicenter study comparing a management strategy
including patient education and monitoring as part of a hospital dedicated organization and
an organization of care as usually done in France.
The primary endpoint was a composite endpoint of morbidity and mortality involving deaths,
unplanned readmissions and emergency visits for heart failure.
The expected number of patients is 720 patients (360 per strategy). The follow-up duration of
24 months.
| Status | Completed |
| Enrollment | 186 |
| Est. completion date | December 2017 |
| Est. primary completion date | December 2017 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 85 Years |
| Eligibility |
Inclusion Criteria: - Chronic heart failure patient with left ventricular ejection fraction (LVEF) defined by an impaired LVEF less than or equal to 40%. - Heart failure stage III or IV NYHA, or heart failure patients with stage II NYHA with previous hospitalization for heart failure. - Patient who has received a written or oral information of the study - Patient affiliated with French health Insurance Exclusion Criteria: - Patient refusal to participate in the study - Progressive neoplastic pathology. - Patient with impaired cognitive functions known. - Patient subject to a measure of socio-legal protection. - Heart failure secondary to curable causes (an arrhythmia, valvular dysfunction, myocardial infarction, bypass surgery scheduled, aortic stenosis, breaking ropeā¦) - Dyspnea pulmonary origin: pulmonary arterial hypertension pre-capillary origin catheterization, defined by a Pcap =15 mmHg. - Patient who underwent ventricular mechanical assistance. - Patient with acute breathlessness is explained by: a severe lung infection (CPT <60% of predicted, ventricular ejection fraction <60% predicted) or pulmonary embolism or respiratory failure with ambient air PaO2 (arterial oxygen pressure) below 60 mmHg or oxygen therapy. - Dialysis patient |
| Country | Name | City | State |
|---|---|---|---|
| France | Hospices Civils de Lyon | Bron |
| Lead Sponsor | Collaborator |
|---|---|
| Hospices Civils de Lyon |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Composite endpoint combining the proportion of patients who died, the proportion of hospitalization for heart failure as well as the proportion of emergency visits for heart failure. | 12 months | ||
| Secondary | Unplanned re hospitalization rate or emergency consultations for cardiac insufficiency. | At 6, 18 and 24 months | ||
| Secondary | Quality of life. | MINNESOTA Questionnaire. | 12 months | |
| Secondary | Satisfaction. | Semi-structured interviews. | 3 months | |
| Secondary | Cost of medical care | Identification of expenditure: Hospitalizations Consultations (inpatient and outpatient) Biology and imaging Medical transport |
24 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03062241 -
Ablation of Atrial Fibrillation in Heart Failure Patients
|
N/A |